Drug Profile
Afuresertib - Laekna Therapeutics
Alternative Names: 2110183; Afuresertib hydrochloride; ASB-183; GSK-2110183; GSK2110183B; GSK2110183C; LAE 002Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Laekna Therapeutics; Novartis Oncology; University Health Network
- Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules; Thiophenes
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase I/II HER2 negative breast cancer; Prostate cancer; Solid tumours
- Discontinued Cancer; Chronic lymphocytic leukaemia; Gastric cancer; Haematological malignancies; Histiocytosis; Multiple myeloma
Most Recent Events
- 11 Dec 2023 Efficacy and safety data from a phase I trial in HER2-negative-breast cancer released by Laekna Therapeutics
- 05 Dec 2023 Efficacy and adverse events data from a phase I trial in HER2-negative-breast-cancer presented at the 46th Annual San Antonio Breast Cancer Symposium, 2023 (SABCS-2023)
- 20 Oct 2023 Updated safety and efficacy data from the phase I/II trial in Prostate cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)